Fibrosis research
June 14, 2016
Boehringer Ingelheim and
Harvard scientists have announced
that they have established a
research alliance to find novel
treatments for severe fibrotic
diseases.
The new research collaborators
have said they aim to discover
better treatments for diseases
like idiopathic pulmonary fibrosis
(IPF), chronic kidney disease (CKD)
and nonalcoholic steatohepatitis
(NASH).
The diseases can affect organs,
such as liver, bone marrow, lung,
kidney, gastrointestinal tract, skin,
eye, and the heart which may lead
to organ failure and death.
The above article was sent to subscribers in Pharmacy Daily's issue from 14 Jun 16To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 14 Jun 16